Anatomic and functional outcome of triamcinolone-assisted 23-gauge vitrectomy in vitreomacular traction syndrome.
OBJECTIVE
To evaluate the outcomes of patients with vitreomacular traction syndrome (VMT) treated with triamcinolone acetonid (TA) assisted 23-gauge (23-G) transconjunctival sutureless vitrectomy.


METHODS
Restrospective, case series. The medical charts of 13 eyes of 13 consecutive patients with VMT who underwent 23-gauge transconjunctival pars plana vitrectomy were reviewed. All patients had at least six-month follow-up. The main outcome parameters were changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) between the baseline and postoperative follow- up examinations performed at the first, third, and sixth months after the surgery.


RESULTS
The mean follow-up period was 7 (range 6-15) months. The mean preoperative BCVA was 1.3±0.4 (logmar). The final BCVA was 0.5±0.3 (logmar) (p = 0.001). The mean CMT was 429±85 µm at baseline, which was significantly reduced to 255±47 µm at the final follow-up visit (p = 0.001). The mean CMT reduction was 174±101 (range: 32-348) µm. No postoperative complications were seen such as endophthalmitis, retinal detachment, hypotony, or glaucoma.


CONCLUSIONS
Triamcinolone assisted 23-G transconjunctival sutureless vitrectomy is an effective and safe surgical technique in the management of VMT syndrome. Further studies with large case series are needed.
Ankara Ataturk Training and Research Hospital First Ophthalmology Department, Ankara, Turkey.
Yasin
Y
Toklu
Sibel
S
Demirel
Ozge
O
Sarac
Hasan Basri
HB
Cakmak
Nurullah
N
Cagıl
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008266:Macula Lutea / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D013536:Suture Techniques; D013577:Syndrome; D014057:Tomography, X-Ray Computed; D014221:Triamcinolone / Q000627:therapeutic use*; D014792:Visual Acuity; D014821:Vitrectomy / Q000379:methods*; D020255:Vitreous Detachment / Q000473:pathology / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D014221:Triamcinolone